Florida is currently home to 3760 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Recruiting
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Galiz Research, Hialeah, Florida
Conditions: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
Recruiting
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoin... Read More
Gender:
ALL
Ages:
39 years and below
Trial Updated:
03/10/2025
Locations: University of Florida, Gainsville, Florida
Conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients with Epilepsy Involving the Temporal Lobe Region.
Recruiting
The 24/7 EEGâ„¢ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region . 2-5 sites in Europe Up to 10 sites in U... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/10/2025
Locations: University of South Florida (USF) Neurology Department, Tampa, Florida
Conditions: Epilepsy
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
Recruiting
The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is safe and tolerable.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/10/2025
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Lung Diseases, Lung Cancer, Protection Against
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
03/10/2025
Locations: Boca Raton Regional Hospital, Boca Raton, Florida
Conditions: Breast Cancer
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
Recruiting
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once week... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/10/2025
Locations: Midland Florida Clinical Research Center, LLC, DeLand, Florida
Conditions: HSV Infection
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Recruiting
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/10/2025
Locations: College of Medicine - Jacksonville University of Florida, Jacksonville, Florida
Conditions: Venous Thromboembolism
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Recruiting
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
03/10/2025
Locations: Johns Hopkins All Children's Heart Institute, Saint Petersburg, Florida
Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Recruiting
TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/09/2025
Locations: D&H Cancer Research Center Llc, Margate, Florida
Conditions: Advanced Cancer, Advanced Solid Tumor
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
Recruiting
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
03/09/2025
Locations: Nicklaus Children's Hospital, Miami, Florida
Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
A Study of LM-24C5 For Advanced Solid Tumors
Recruiting
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2025
Locations: Ocala Oncology, Ocala, Florida
Conditions: Advanced Solid Tumor
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab and polatuzumab vedotin are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Polatuzumab, linked to a toxic agent call... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma